{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-040386","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.762072+00:00","generated_at":"2026-05-23T03:30:17.704288+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"confidence":"high","headline":"GlycoMimetics amends Crescent merger; exchange ratio ~15.42 GLYC shares per Crescent share","bullets":["Amendment clarifies Crescent RSUs will be assumed using the same exchange ratio as other Crescent securities.","Each Crescent share to receive approximately 15.4192 shares of GlycoMimetics common stock.","Post-merger, GlycoMimetics holders expected to own ~2.6%; Crescent holders ~97.4% (fully diluted).","GlycoMimetics net cash at closing assumed at $1.8 million for ownership calculation.","Certificate of Designation for Series A Non-Voting Preferred Stock updated to clarify voting mechanics."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-040386","json":"https://secwatch.observer/filing/0001104659-25-040386.json","markdown":"https://secwatch.observer/filing/0001104659-25-040386.md","text":"https://secwatch.observer/filing/0001104659-25-040386.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925040386/0001104659-25-040386-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925040386/tm2513409d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T03:30:17.704288+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}